Holen Sie sich die Stockscreener-App
9.24
3.82%
0.34
Vorhandelsmarkt:
9.28
0.04
+0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Viatris Inc Aktie (VTRS) Neueste Nachrichten
What analysts say about Viatris Inc. stockExplosive capital appreciation - jammulinksnews.com
Is Viatris Inc. a good long term investmentExplosive capital appreciation - jammulinksnews.com
What drives Viatris Inc. stock priceFree Trend-Following Techniques - jammulinksnews.com
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest
Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest
Trend Tracker for (VTRS) - news.stocktradersdaily.com
Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga
Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com
Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's
Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest
Why Is Viatris Stock Falling In Pre-market? - Nasdaq
Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha
Viatris eye ointment fails late-stage study, shares fall - TradingView
Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com
Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com Australia
Viatris eye therapy fails to meet late-stage trial goal - TradingView
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire
Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN
Hypopituitarism Treatment Market Expansion Supported - openPR.com
Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest
Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey
Viatris' Canadian Workplace Excellence Fuels Long-Term Resilience in Pharma's Turbulent Landscape - AInvest
Viatris Certified as a Great Place to Work® in Canada - Yahoo Finance
What makes Viatris Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru
Non-Opioid Patch Market CAGR 6.6 percent overview and leading - openPR.com
Viatris Inc. (VTRS) Stock Analysis: Evaluating a 24.86% Potential Upside Amidst Financial Headwinds - DirectorsTalk Interviews
Theravance higher as China approves Viatris-partnered COPD therapy - MSN
J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug - Seeking Alpha
When (VTRS) Moves Investors should Listen - news.stocktradersdaily.com
0.96%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):